ICON reported third-quarter revenue of $2.02 billion and adjusted earnings of $2.66 a share, with net business wins of $3.15 billion lifting its backlog to $24.5 billion.
ICON plc, the Dublin-based clinical research organisation, reported third-quarter 2026 revenue of $2,024.8 million, down 2.9 percent from a year earlier and down 2.5 percent on a constant currency basis. Adjusted net income was $205.8 million, or $2.66 adjusted diluted earnings per share, up 3.9 percent on the second quarter of 2026, while GAAP net income was $122.1 million, or $1.58 a share. Adjusted EBITDA was $336.9 million, a margin of 16.6 percent.
Commercial performance was the quarter's strength. Gross bookings were $3,789 million, up 26.9 percent on the third quarter of 2025, and after cancellations of $639 million, net business wins were $3,150 million, a book-to-bill ratio of 1.56 times. Backlog at September 30 was $24.5 billion, up 4.8 percent sequentially. The company generated free cash flow of $302.4 million in the quarter.
ICON returned $400 million to shareholders through share repurchases in the quarter at an average price of $170 a share, and its board approved an increase in the share buyback authorization, bringing the total authorized value to $750 million to be deployed opportunistically. Chief executive Barry Balfe said he was pleased with the quarter's financial, operational and commercial execution, pointing to adjusted EBITDA growth of 3 percent sequentially on improved business mix and cost discipline, and said the company's AI-enabled digital platform continues to resonate with customers.
The company's release supplies the figures used here, and Zacks independently reports the same $2.66 earnings and $2.02 billion revenue totals. Providers differ on the consensus estimates for the quarter, so no consensus figure is used in this report. The updated full-year guidance reflects sustained operational progress and higher pass-through activity, according to the release.
The bookings and backlog figures matter more for ICON than a single quarter's revenue, because contracted work converts into revenue over the life of a trial. A $24.5 billion backlog, a 1.56 book-to-bill ratio and a larger buyback authorization together point to a company choosing to return cash while its order book grows, and the updated full-year guidance, not the quarterly revenue dip, is what the company pointed investors to.